Colonia Care Pharmacy, Colonia, NJ
Is Colonia Care Pharmacy registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Colonia Care Pharmacy hold a New Jersey pharmacy license?
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
Has Colonia Care Pharmacy had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 2 Form 483s (Apr 29, 2019 and Jul 26, 2021) for Colonia Care Pharmacy. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Colonia Care Pharmacy
- Location
- Colonia, NJ
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jul 13, 2023
- FDA Data Dashboard inspections
- 3 inspections: 3 OAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 8 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Colonia Care Pharmacy, a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Jul 13, 2023 | Other | State Action Letter Issued 7/13/2023 | FDA copy (archived) |
| Aug 17, 2021 | Response to Form 483 | 483 Response Dated 08/17/2021 | fda.gov |
| Jul 26, 2021 | Form 483 | 483 Issued 07/26/2021 | fda.gov |
| Apr 29, 2019 | Form 483 | 483 Issued 04/29/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Colonia Care Pharmacy, Colonia, NJ (FEI number 3012223534), matched to this page by exact name, city and state. It lists 3 inspections: 3 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 26, 2021 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012223534 | 1147167 |
| Apr 22, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012223534 | 1088095 |
| Apr 15, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012223534 | 984885 |
Form 483s FDA has published for this site
- Jul 26, 2021: Form 483 to Colonia Care Pharmacy, published Oct 20, 2021. fda.gov
- Apr 29, 2019: Form 483 to Colonia Care Pharmacy, published Jul 25, 2019. fda.gov
- Aug 16, 2016: Form 483 to Colonia Care Pharmacy, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 8 numbered observations in all, across 2 inspections ending Apr 15, 2016 to Jul 26, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jun 9, 2021 to Jul 26, 2021: 3 observations
- Firm on the cover
- Colonia Care Pharmacy, 515 Inman Ave Ste A, Colonia, NJ 07067-1114
- FEI number
- 3012223534
- Establishment type on the cover
- Compounding Pharmacy
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Non-microbial contamination was observed in your production area.
Specifica lly,
a. On 6/9/2021, we observed an unknown white to off-white powder residue and light brownish discoloration under the front return air grille located inside the ISO 5 <Redacted B4> Laminar Flow <Redacted B4> (LF <Redacted B4>), which was documented as having been cleaned the day before on 6/8/2021.
b. The unclassified room where the ISO 5 LF <Redacted B4> is located is held under insanitaiy conditions. This unclassified room is utilized for the compounding of non-sterile drug products. We observed the following, but not limited to:
i Dust/filth on HVAC vent and on the surface of chemo/hazardous wipe bags stored on the shelf.
cted B4> ii lll. Off-white to yellowish substance stuck on the ceiling .
Wood en blocks to support the four legs of LF <Reda
iv. Dust/filth on multiple appliances such as, but not limited to, the surface of the weighing balance, computer, camera and keyboard.
v. Discoloration/dark stain on the vinyl-like floor.
vi. Rust-like appearance ( orange/reddish material) on the nails on a shelf where active pharmaceutical ingredients and raw materials are stored.
Observation 2
The use of sporicidal agents in the ISO 5 classified aseptic processing area was inadequate and infrequent.
Specifica lly,
4 a. The cleaning logs indicated that the sporicidal cleaning of the ISO 5 LF <Redacted B4> was performed <Redacted B4>. You stated that the sporicidal cleaning is performed at the discretion of the pharmacist. You did not provide any scientific rationale for the frequency of sporicidal cleaning. In addition, the contact time for the use of sporicidal cleaning agent is unknown from the documents provided.
b. On 6/25/2021, we observed that the pharmacist conducting routine cleaning of the ISO 5 LF <R
edacted B4> did not clean the supply air grille located below the HEPA filter nor the surface of the l atex glove sleeves. Thes e sur faces ai·e lo cate d <Redacted B4> where ste rile products are o pe n to th e en vi ronm en t d uring compou nding manipul ations inside the LF <R ed acted B4>.
C. The Februar y 2021 cleaning lo g of the ISO 5 L F <Redacted B4> indicated that no cleaning w as performed from 2/23/2021 to 2/28/2021. The <Redacted B4> operation checklist indicated that the <Redac ted B4> was not in use during this period. However, your prescription re ...
Observation 3
You produced highly potent diugs without providing adequate containment, segregation, cleaning of work surfaces, cleaning of utensils and cleaning of personnel to prevent cross-contamination.
Specifically,
Your firm compounds sterile/non-sterile drug products such as, but not limited to betalactams, opioids, antineoplastic, and hormonal products. However, no cleaning agent is currently utilized that would render these compounds inactivated and removed from product contact surfaces. In addition, cleaning activities after compounding operations are not documented and cannot not be verified.
cleaning activities after compounding operations are not documented and cannot not be verified.
Inspection Mar 3, 2016 to Apr 15, 2016: 5 observations
- Firm on the cover
- Colonia care Pharmacy, 515 Inman Ave Ste A
- FEI number
- 3012223534
- Establishment type on the cover
- Producer of Sterile Drug Products Colonia, NJ 07067-1114
- FDA district office on the cover
- Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, there is insufficient test data supporting the labeled Beyond Use Date (BUD) provided for s ome i njectable products or in process sterile-filtered stock solutions used to prepare them. For example:
• Papaverine/Phentolamine/Prostaglandin-E I ll1iection Solution ("Trimix"), lot 020216A, was prepared and filled on 2/2/16 in a multi-use vial, with a BUD of 30 days refrigerated, and 6 months when frozen. The finished product was not tested for sterility, and was made using in house stock solutions prepared from non-sterile Starting materials, one of which was expired (Papaverine stock solution expired approx. 23 days earlier, on 1/10/2016).
Each stock injection solution was prepared in multi-use vial, and assigned a BUD of 1 to 6 months after filter sterilization, and stored in an unclassified area (Papaverine stock solution produced on 12/11/15, BUD 01/10/16; Phentolamine stock solution produced on 12/03/15, BUD 05/31/16; and Alprostadil stock solution produced on 12/11/15, BUD 06/08/16). a ...
Observation 2
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory .conformance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically, not all finished sterile drug products are tested for sterility and endotoxin levels, where appropriate, and there is no testing schedule. For example:
• Papaverine/Phentolamine/Prostaglandin-EI Injection Solution ("Trimix"),lot 020216A, was prepared and filled on 2/2/16, and given a BUb of30 days refrigerated, and 6 months when frozen. There was no testing of sterility or endotoxin levels of the finished drug product.
• Methylcobalamin andAcetylcysteine InJection Solution, lot 120715M, was prepared and filled on 12/07/15, and given a BUD of 30 days refrigerated, and 6 months when frozen. There was no testing of sterility or endotoxin levels of the finished drug product.
•· Atropine Ophthalmic Solution, lot 0203161, was prepared and filled on 02/03/16, and given a BUD of 3 months. There was no testing of sterility of the finished drug product. ...
Observation 3
f Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, in the laminar flow glovebox, which is located in an unclassified room and is used for aseptic filling of sterile drug products, the evaluation of unidirectional airflow continuity, (e.g., smoke studies), airborne viable and non-viable particle counts, and surface monitoring for microbiological contamination are not performed under dynamic conditions that represent routine usage.
The air and surface monitoring are performed twice annually during recertification of the laminar flow glovebox when it is not being used, and not .routinely during aseptic filling, which may occur daily or multiple times throughout the week. In addition, personnel monitoring consists of gloved fingertip monitoring (sterile gloves are donned over the gauntlet-gloves) every six months, and is performed as an independent operation, not after completion of aseptic filling, to represent routine conditions.
Observation 4
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
Specifically, twice-annual media fill testing is performed to support aseptic filling practices, in which 100ml of soybean casein digest media is prepared, sterile filtered, and filled into an unspecified number of "10 ml" vials, with a 5 ml control sample. This does not represent the most challenging conditions, in that up to 30 vials may be filled at one time. For example, Dexamethasone 24mg/ml Injectable, lot 0317l6N, was prepared on 3/17/16, and filled into 30 vials.
Observation 5
Container closure systems do not provide adequate protection against foreseeable external factors in storage and. use that can cause deterioration or contamination of the drug product.
Specifically, the filling record for Papaverine/Phentolamine/Prostaglandin-El Injection Solution lot 0 20216A; executed 2/2/16 notes "Protect from light'\ but the finished drug product is prepared in “30ml Cle ar Sterile vial". Ther e is no assurance the drug is adequately protected from light.
Linked 483s whose text is not shown
- Apr 29, 2019: FDA document 128378: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.